A Phase II Safety and Tolerability Study With SEN0014196
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is
administered orally over 12 weeks to male and female patients with Huntington's Disease.